ArticleCancer medicine2023
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 25 citations in OpenAlex.
- Increased Lymphocyte Proportions as a Candidate Biomarker for Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy.Cancer medicine · 2026Article
- Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.Cancer medicine · 2026Article
- Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer.Cancer reports (Hoboken, N.J.) · 2026Article
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.Clinical journal of gastroenterology · 2026Article
- Article
- Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.Cancer medicine · 2026Observational
- Article
- Hematologic toxicity of immune checkpoint inhibitors: real-world burden and risk profiles from a five-year cohort from the Middle East.BMC cancer · 2026Article
- Article
- Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review.Journal of pharmaceutical health care and sciences · 2026Article
- Impact of high relative dose intensity on effectiveness and treatment continuity of IO-TKI therapy in Japanese advanced renal cell carcinoma.Scientific reports · 2026Article
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Article
- Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis.JTO clinical and research reports · 2026Article
- Toward nursing-integrated biomarker surveillance for immune-related adverse events during immune checkpoint inhibitor therapy.Frontiers in medicine · 2026Review
- Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer.Frontiers in immunology · 2026Article
- Divergent Outcomes in Lung Adenocarcinoma with Paraneoplastic Hypereosinophilia in Patients Treated with Pembrolizumab: A Two-Case Report.International medical case reports journal · 2026Article
- Pembrolizumab-Induced Colitis With Concurrent Capecitabine in Triple-Negative Breast Carcinoma: A Case Report.Cureus · 2026Article
- Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab.International journal of clinical oncology · 2025Article
- Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist.Journal of neurology, neurosurgery, and psychiatry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) can cause severe immune-related adverse events (irAEs). However, biomarkers for irAEs common to different types of ICIs and cancers have not been reported. This study examined whether eosinophils can be used as a predictor of irAEs.
methodsSix hundred fourteen patients with cancer (esophageal, gastric, head and neck, lung, melanoma, renal cell, urothelial, and other cancer) received anti-PD-1, anti-PD-L1, or anti-CTLA-4 plus anti-PD-1 therapy. The patients were divided into two groups depending on whether they experienced irAEs (irAE group) or not (non-irAE group). Eosinophils were examined before the two-course treatment.
resultsPatients in the irAE group who received anti-PD-1 or anti-CTLA-4 plus anti-PD-1 therapy had higher eosinophils before the two-course treatment than those in the non-irAE group (p < 0.05). The eosinophils in the anti-PD-L1 therapy group tended to increase in the irAE group. Furthermore, eosinophils in gastric, head and neck, lung, melanoma, renal, and urothelial cancers were significantly higher in the irAE group than in the non-irAE group (p < 0.05). The optimal cutoff value for eosinophils against irAEs was 3.0% (area under the curve = 0.668). In multivariate analyses, eosinophils of ≥3.0% were an independent factor for irAEs (odds ratio: 2.57, 95% CI: 1.79-3.67).
conclusionAn increased eosinophil before the two-course treatment may be a predictor of irAEs in various cancers treated with different ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.